WO2003076461A3 - Dimeres antagonistes du tf - Google Patents

Dimeres antagonistes du tf Download PDF

Info

Publication number
WO2003076461A3
WO2003076461A3 PCT/DK2003/000151 DK0300151W WO03076461A3 WO 2003076461 A3 WO2003076461 A3 WO 2003076461A3 DK 0300151 W DK0300151 W DK 0300151W WO 03076461 A3 WO03076461 A3 WO 03076461A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimeric
antagonist
factor vii
vii polypeptides
polypeptides
Prior art date
Application number
PCT/DK2003/000151
Other languages
English (en)
Other versions
WO2003076461A2 (fr
Inventor
Marianne Kjalke
Palle Jakobsen
Henning Ralf Stennicke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to AU2003214023A priority Critical patent/AU2003214023A1/en
Priority to EP03709668A priority patent/EP1485476A2/fr
Priority to JP2003574676A priority patent/JP2005538936A/ja
Publication of WO2003076461A2 publication Critical patent/WO2003076461A2/fr
Publication of WO2003076461A3 publication Critical patent/WO2003076461A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des polypeptides FVII dimères se fixant à, et inhibant, simultanément, deux molécules de TF.
PCT/DK2003/000151 2002-03-12 2003-03-12 Dimeres antagonistes du tf WO2003076461A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003214023A AU2003214023A1 (en) 2002-03-12 2003-03-12 Dimeric tf antagonist comprising two factor vii polypeptides
EP03709668A EP1485476A2 (fr) 2002-03-12 2003-03-12 Dimeres antagonistes du tf
JP2003574676A JP2005538936A (ja) 2002-03-12 2003-03-12 二量体のｔｆアンタゴニスト

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200373 2002-03-12
DKPA200200373 2002-03-12

Publications (2)

Publication Number Publication Date
WO2003076461A2 WO2003076461A2 (fr) 2003-09-18
WO2003076461A3 true WO2003076461A3 (fr) 2004-03-18

Family

ID=27798725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000151 WO2003076461A2 (fr) 2002-03-12 2003-03-12 Dimeres antagonistes du tf

Country Status (4)

Country Link
EP (1) EP1485476A2 (fr)
JP (1) JP2005538936A (fr)
AU (1) AU2003214023A1 (fr)
WO (1) WO2003076461A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1893631B1 (fr) * 2005-06-17 2013-08-14 Novo Nordisk Health Care AG Composés fviia dimères et multimères

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010191A1 (fr) * 1992-10-30 1994-05-11 Novo Nordisk A/S Proteines faiblement allergenes
WO1994014467A1 (fr) * 1992-12-29 1994-07-07 Genentech, Inc. Traitement d'affections intestinales inflammatoires par des inhibiteurs d'interferon-gamma.
US5874407A (en) * 1995-12-04 1999-02-23 Genentech, Inc. Factor VIIA inhibitors
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO2001002439A1 (fr) * 1999-07-01 2001-01-11 Yale University Immunoconjugues cibles neovasculaires
WO2001021661A1 (fr) * 1999-09-20 2001-03-29 Novo Nordisk A/S INHIBITEUR BIVALENT DU COMPLEXE FVIIa/TF/FXa
WO2002002764A2 (fr) * 2000-06-30 2002-01-10 Regents Of The University Of Minnesota Derives a poids moleculaire eleve de polypeptides dependant de la vitamine k

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1994010191A1 (fr) * 1992-10-30 1994-05-11 Novo Nordisk A/S Proteines faiblement allergenes
WO1994014467A1 (fr) * 1992-12-29 1994-07-07 Genentech, Inc. Traitement d'affections intestinales inflammatoires par des inhibiteurs d'interferon-gamma.
US5874407A (en) * 1995-12-04 1999-02-23 Genentech, Inc. Factor VIIA inhibitors
WO2001002439A1 (fr) * 1999-07-01 2001-01-11 Yale University Immunoconjugues cibles neovasculaires
WO2001021661A1 (fr) * 1999-09-20 2001-03-29 Novo Nordisk A/S INHIBITEUR BIVALENT DU COMPLEXE FVIIa/TF/FXa
WO2002002764A2 (fr) * 2000-06-30 2002-01-10 Regents Of The University Of Minnesota Derives a poids moleculaire eleve de polypeptides dependant de la vitamine k

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONATE F ET AL: "Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X.", BIOCHEMISTRY, vol. 39, no. 37, 2000, pages 11467 - 11476, XP002902962 *

Also Published As

Publication number Publication date
AU2003214023A8 (en) 2003-09-22
AU2003214023A1 (en) 2003-09-22
JP2005538936A (ja) 2005-12-22
EP1485476A2 (fr) 2004-12-15
WO2003076461A2 (fr) 2003-09-18

Similar Documents

Publication Publication Date Title
WO2003072803A3 (fr) Nanostructures contenant des unites d'assemblage d'anticorps
WO2006066024A3 (fr) Motifs de famille de polypeptides pancreatiques, polypeptides et leurs methodes
EP1429665A4 (fr) Agrafe composite pour realiser une anastomose
EP1578930A4 (fr) Polypeptides cngh0004, anticorps, compositions, procedes et utilisations
EP1617769A4 (fr) Structures, systemes et procedes servant a relier ou joindre ensemble des articles et materiaux, et leurs utilisations
WO2006097536A3 (fr) Agonistes a base de peptide dimere contre le recepteur de glp-1
EP2284180A3 (fr) Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
WO2006013202A3 (fr) Conjugaison de fvii
AU2003256001A1 (en) Fusion protein comprising angiopoietin receptor-binding and a multimerization domain
DK1047781T3 (da) IL-18-receptorer
EP1786273A4 (fr) Mecanismes d'isolement et de purification sequentiels de proteines par chromatographie d'affinite
EP1617802A4 (fr) Polynucleotides specifiques de cngh0010, polypeptides, anticorps, compositions, methodes et utilisations
ATE452646T1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
BR0200820B8 (pt) tirante de ligaÇço em compàsito.
BR0208469B1 (pt) isqueiro.
WO2007053570A3 (fr) Complexe polypeptidique de trpm8 et de calmoduline et tissus correspondants
WO2005000876A3 (fr) Proteines de la famille des proteines a doigts de zinc (ring finger) et leurs utilisations
WO2003076461A3 (fr) Dimeres antagonistes du tf
FI20031719A (fi) Järjestelmät, menetelmät ja tuotantotavarat valinta- ja vieritystoiminnolla varustetun rajapinnan muodostamiseksi
WO2005037236A3 (fr) Nouveaux polypeptides associes a la proteine de choc thermique 20 et utilisations
WO2003087051A3 (fr) Procedes d'identification de sites allosteriques
WO2004005351A3 (fr) Anticorps specifiques de neoplasme et utilisations associees
WO2007002096A3 (fr) Methodes et compositions permettant de cibler ifnar2
WO2004092332A3 (fr) Polypeptides de virus de sars
AU2003304409A1 (en) Evaluating protein signatures

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003709668

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003574676

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003709668

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003709668

Country of ref document: EP